Outcomes of multimodality therapies for patients with stage II or III rectal cancer in California, 1994-2009

Diseases of the Colon and Rectum

Volumn 56, Issue 12, 2013, Pages 1357-1365

  Cho, Myung Mi ^a,b   Morgan, John W ^a,c   Knutsen, Raymond ^a   Oda, Keiji ^a   Shavlik, David ^a   Knutsen, Synnove ^a   Kazanjian, Kevork ^d  

^a LOMA LINDA UNIVERSITY   (United States)

^b Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^c Desert Sierra Cancer Surveillance Program   (United States)

^d LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Multimodality therapy; Perioperative chemoradiation; Rectal cancer; Survival

Indexed keywords

ADENOCARCINOMA; AGED; CALIFORNIA; CHEMORADIOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84888373550     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/01.dcr.0000436362.81611.de     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62: 10-29.
2. California Cancer Facts & Figures 2012. Expected new cancer cases & deaths in California-2012. http://www.ccrcal.org/pdf/ Reports/ACS-2012. pdf. Accessed March 3, 2012.
3. Yorio JT, Bhadkamkar NA, Kee BK, Garrett CR. A primer on the current state-of-the-science neoadjuvant and adjuvant therapy for patients with locally advanced rectal adenocarcinomas. Int J Surg Oncol. 2012;2012:863034.
4. Gastrointestinal Tumor Study Group. Prolongation of the disease- free interval in surgically treated rectal carcinoma. N Engl J Med. 1985;312: 1465-1472.
5. Douglass HO Jr, Moertel CG, Mayer RJ, et al. Survival after postoperative combination treatment of rectal cancer. N Engl J Med. 1986;315: 1294-1295.
6. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264: 1444-1450.
7. Junginger T, Hossfeld DK, Sauer R, Hermanek P. Adjuvante therapie bei kolon- und rektumkarzinom. Dtsch Ärztebl. 1999;96:A-698-700.
8. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336: 980-987.
9. Cammà C, Giunta M, Fiorica F, Pagliaro L, Craxì A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: a metaanalysis. JAMA. 2000;284: 1008-1015.
10. Peeters KC, Marijnen CA, Nagtegaal ID, et al.; Dutch Colorectal Cancer Group. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246: 693-701.
11. van Gijn W, Marijnen CA, Nagtegaal ID, et al.; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year followup of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12: 575-582.
12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. http://www. tri-cobe.org/nccn/guideline/colorectal/ english/rectal.pdf. Accessed October 5, 2013.
13. Edge SB, Byrd DR, Compton CC, et al, eds. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 7th ed. New York, NY: Springer-Verlag; 2010.
14. Glimelius B, Påhlman L, Cervantes A; ESMO Guidelines Working Group. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v82-v86.
15. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012;23: 2479-2516.
16. Surveillance Epidemiology and End Results (SER) website. SER Data, 1973-2008. http://www.seer.cancer.gov/registries/ data.html. Updated October 21, 2011. Accessed March 4, 2012.
17. Public Health Institute. Cancer California Registry Data Dictionary. http://www.ccrcal.org/pdf/data-statistics/data-dictionary. pdf. Updated July 9, 2008. Accessed January 30, 2013.
18. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12: 703-711.
19. SAS (Version 9.3) [computer program]. Cary, NC: SAS Institute; 2011.
20. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002;20: 1192-1202.
21. Neugut AI, Fleischauer AT, Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol. 2002;20: 2643-2650.
22. Sargent DR, Goldberg J, MacDonald J, et al. Adjuvant chemotherapy for colon cancer is beneficial without significantly increased toxicity in elderly patients: Results from a 3,351 patient meta-analysis. Proc Am Soc Clin Oncol. 2000;19:241a(abstr 933).
23. Aschele C, Guglielmi A, Tixi LM, et al. Adjuvant Treatment of Colorectal Cancer in the Elderly. Cancer Control. 1995;2(2 suppl 1): 36-38.
24. Lebwohl B, Ballas L, Cao Y, et al. Treatment interruption and discontinuation in radiotherapy for rectal cancer. Cancer Invest. 2010;28: 289-294.
25. Zutshi M, Hull T, Shedda S, Lavery I, Hammel J. Gender differences in mortality, quality of life and function after restorative procedures for rectal cancer. Colorectal Dis. 2013;15: 66-73.
26. Martinez SR, Chen SL, Bilchik AJ. Treatment disparities in Hispanic rectal cancer patients: a SER database study. Am Surg. 2006;72: 906-908.
27. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute. http://seer.cancer. gov/csr/1975-2009-pops09/. Accessed April 15, 2012.
28. Morgan JW, Cho MM, Guenzi CD, et al. Predictors of delayedstage colorectal cancer: are we neglecting critical demographic information? Ann Epidemiol. 2011;21: 914-921.
29. US Department of Health and Human Services. National Healthcare Disparities Report 2011. AHRQ Publication No. 12-0006. http://www.ahrq.gov/qual/ qrdr11.htm. Accessed July 29, 2012.
30. Kim J, Artinyan A, Mailey B, et al. An interaction of race and ethnicity with socioeconomic status in rectal cancer outcomes. Ann Surg. 2011;253: 647-654.
31. Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, eds. Cancer Management: A Multidisciplinary Approach. 11th ed. Manhasset, NY: CMP Medica; 2009.
32. Galvin JM, Ezzell G, Eisbrauch A, et al.; American Society for Therapeutic Radiology and Oncology; American Association of Physicists in Medicine. Implementing IMRT in clinical practice: a joint document of the American Society for Therapeutic Radiology and Oncology and the American Association of Physicists in Medicine. Int J Radiat Oncol Biol Phys. 2004;58: 1616-1634.
33. California Health and Safety Code, sections 103875-103885. http://www.leginfo.ca.gov/cgi-bin/displaycode?section=hsc&g roup=103001-104000&file=103875-103885. Accessed April 8, 2013.
34. Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA. Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst. 2002;94: 835-844.